| Identification | Back Directory | [Name]
Gantofiban | [CAS]
183547-57-1 | [Synonyms]
Gantofiban
EMD 151201
YNBHAPKHWDNTMZ-QGZVFWFLSA-N
2-[4-[3-[4-[N1-(Methoxycarbonyl)amidino]phenyl]-2-oxooxazolidin-5(R)-ylmethyl]piperazin-1-yl]acetic acid ethyl ester
4-[[(5R)-3-[4-[Imino[(methoxycarbonyl)amino]methyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-1-piperazineacetic acid ethyl ester
1-Piperazineacetic acid, 4-[[(5R)-3-[4-[imino[(methoxycarbonyl)amino]methyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, ethyl ester | [Molecular Formula]
C21H29N5O6 | [MOL File]
183547-57-1.mol | [Molecular Weight]
447.48 |
| Hazard Information | Back Directory | [Uses]
Gantofiban is a GPIIb/IIIa integrin receptor antagonist. By binding to this receptor, Gantofiban can effectively inhibit platelet aggregation, thereby exerting its antithrombotic effect[1]. | [References]
[1] Schulte M, et al. Enantioseparation of gantofiban precursors on chiral stationary phases of the poly-(N-acryloyl amino acid derivative)-type. J Pharm Biomed Anal. 2002 Jan 15;27(3-4):627-37. DOI:10.1016/s0731-7085(01)00651-3 |
|
|